Summary
Regeneron Pharmaceuticals, Inc. (REGN) announced on September 25, 2011, the presentation of data from its Phase 3 VELOUR trial at the European Multidisciplinary Cancer Congress. The trial evaluated ZALTRAP™ (aflibercept), also known as VEGF Trap, in combination with the FOLFIRI chemotherapy regimen for patients with previously treated metastatic colorectal cancer. The results, presented by Prof. Josep Tabernero, are considered a significant event for investors interested in the company's oncology pipeline. The furnished presentation details results from prespecified subgroup analyses of the VELOUR study. This data likely provides further insights into the efficacy and safety of ZALTRAP™ across different patient demographics, which is crucial for understanding its potential market penetration and clinical value. Investors should pay close attention to the detailed findings within Exhibit 99.1 for a comprehensive understanding of the trial's outcomes and their implications for Regeneron's future prospects.
Key Highlights
- 1Presentation of Phase 3 VELOUR trial data for ZALTRAP™ (aflibercept) at the European Multidisciplinary Cancer Congress.
- 2ZALTRAP™ was evaluated in combination with FOLFIRI chemotherapy for metastatic colorectal cancer.
- 3The trial specifically focused on patients with previously treated disease.
- 4Data presented included results from prespecified subgroup analyses, offering deeper insights into treatment effectiveness.
- 5The presentation materials are furnished as Exhibit 99.1 to the 8-K filing.
- 6This event is a key disclosure regarding Regeneron's oncology drug development.